In normal subjects radioactive copper injected intravenously in trace amounts is cleared very rapidly from the plasma-almost entirely by the liver. In patients with Wilson's disease (hepatolenticular degeneration), the plasma clearance of radiocopper is measurably slower and the hepatic uptake appears to be impaired (Osborn and Walshe, 1961; Sass-Kortsak, Glatt, Cherniak, and Cederlund, 1961) . Following prolonged penicillamine therapy which reduces the hepatic copper concentration in these patients the liver uptake of copper returns towards normal, and it has been proposed that the impaired liver copper uptake in Wilson's disease is primarily an expression of the high liver copper level (Osborn and Walshe, 1967) .
If this hypothesis were true, it would be expected that patients with prolonged biliary obstruction, in whom the liver copper concentration is raised to a degree comparable to that in Wilson's disease (Smallwood, Williams, Rosenoer, and Sherlock, 1968) , would handle intravenously injected radiocopper in the same way as patients with Wilson's disease. In the present study, the plasma disappearance and liver uptake of "4CU in patients with
Wilson's disease were compared with those of patients with primary biliary cirrhosis.
Methods
The informed consent of all subjects used in this Received for publication 30 September 1970. investigation was obtained. Radiocopper studies were performed on four patients with Wilson's disease and four patients with primary biliary cirrhosis (Table I) . Two control groups were also studied: three patients with hepatocellular disease and three normal subjects. The patients with Wilson's disease had been on penicillamine therapy (0.9-142 g daily) for four to eight years, and this was temporarily stopped 48-72 hours before each study. Three had had neurological manifestations only and the fourth had well compensated cirrhosis. In the patients with primary biliary cirrhosis and those with hepatocellular disease there was no evidence of ascites, a bleeding tendency, or portal systemic encephalopathy. Normal subjects comprised one woman and two men convalescing after minor orthopaedic procedures, all with no evidence of liver dysfunction.
EXPERIMENTAL DESIGN
At time zero, an accurately weighed dose (14.5-34.0 ,g) of "4CuCI2 (100 ,uCi) was injected into the antecubital vein. The radiation dose of 100 ,Ci of "4Cu (which decays with a half-life of 12.8 hours by electron capture, emitting a positron) is very small. Assuming total retention of the isotope in the liver, 100 ,uCi would give approximately 0-4 rems. Multiple venous blood samples were taken over the next six hours, and total output of urine was collected over the same period. To assess liver uptake of radiocopper, counting was carried out over the surface of the liver using a collimated 139 probe at regular intervals over 30 hours. Care was taken to ensure that the collimator was positioned in precisely the same way for each reading. A sealed counting standard, made up of a known aliquot of the injected dose, was counted before and after each reading to allow correction for any fluctuations in counting efficiency.
There were no sites of accumulation of radioactivity other than the liver detectable by surface counting in any of the four groups of patients.
ANALYSES
In those subjects who underwent liver biopsy as part of their clinical management, the liver copper content was measured by neutron activation analysis (Todd, Thorpe, and Rosenoer, 1967) . Plasma copper levels were measured by atomic absorption spectrophotometry, and plasma caeruloplasmin levels by immunodiffusion. Assuming 8 copper atoms per molecule of caeruloplasmin (MW 160,000 daltons), the amounts of caeruloplasmin-bound and 'free', ie, that bound to albumin and amino acids, copper in plasma could be calculated. Plasma samples (4 ml) were counted in a Packard Auto Gamma spectrometer against a standard prepared from a weighed aliquot of the injected dose.
Plasma volumes were measured using 1-2 ,uCi of 1311-human serum albumin, uptake of 1311 by the thyroid being prevented by the administration of potassium iodide (200 mg daily) for two weeks.
To separate caeruloplasmin-bound "4Cu from 'free' "4Cu, the following procedure was carried out. An equal volume (4 ml) of 2% diethylenetriaminepenta-acetic acid (DTPA), a copper chelating agent, was added to each plasma sample. Globulins were precipitated by adding an equal volume of saturated ammonium sulphate. After standing for one hour, samples were centrifuged at 13,000 g for 20 minutes, and the supernatant decanted. The precipitate was washed three times with 50% ammonium sulphate, redissolved in 4M urea, and again counted against the standard. The initial count gave the total plasma "4Cu, the final count the caeruloplasmin bound "4CU. The 'free' "4Cu was obtained by difference. Preliminary studies in which "4Cu was added to plasma samples showed that less than 5% of the radiocopper (all 'free' in this case) was recovered in the washed precipitate. In patients with Wilson's disease, no activity was detected in the ammonium sulphate precipitate.
The urine output after six hours was measured, and a 4 ml aliquot counted with the plasma samples. As the radioactive half-life of "4CU iS short (12.8 hours), the time of counting of each sample was carefully noted and appropriate corrections were made for radioactive decay.
Results
The liver copper levels (Table I ) determined in the patients with primary biliary cirrhosis ranged from 367 to 714 ,ug/g dry liver, concentrations well above the lower limit (250 ,ug/g dry liver) of the levels found in Wilson's disease (Smallwood et al, 1968; Sternlieb and Scheinberg, 1968) . In one ofthe patients with Wilson's disease treated with penicillamine for four years, the liver copper was 250 ,ug/g dry liver.
No levels were obtained in the other three cases. The three patients with hepatocellular disease had normal or near normal liver copper concentrations (43-70 ,ug/g dry liver).
The plasma 'free' copper concentrations in the two control groups and in the four patients with Wilson's disease were within the normal range of their initial value 26.8 minutes earlier than in Wilson's disease (P < 001). No significant difference was found when primary biliary cirrhosis was compared with the two control groups (Table II) . The rate of disappearance of radiocopper from plasma did not correlate with the liver copper concentration.
Very little of the administered radiolabel was excreted in urine in the first six hours (Table III) (Cumings, 1959) . Moreover, treatment directed at removing copper from the body leads to marked clinical improvement (Walshe, 1963 (Sass-Kortsak, 1965) . Radiocopper studies utilizing both counting of plasma samples and collimated counting over the liver have enhanced our understanding of copper metabolism and have revealed that, after intravenous injection of "4CU into normal subjects, the tracer disappears very rapidly from the plasma, due in large measure to uptake by the liver. The present study has confirmed that in patients with Wilson's disease, the 'plasma disappearance of "4Cu is measurably slower, apparently due to an impaired rate of uptake by the Wilsonian liver.
In attempting to understand the abnormality of copper transport in Wilson's disease, it is important to consider the limitations of the present data. It was not possible to determine the proportion of the injected "4Cu in the liver or other body tissues at any time during the studies. However, a sequence of changes of the level of radioactivity in the liver was demonstrated by the surface counting techniques used. The patients with primary biliary cirrhosis did not differ significantly from normal subjects in this respect: the patients with Wilson's disease had a markedly different pattern of liver copper uptake. The normal plasma clearance, normal urinary excretion, and normal pattern of hepatic uptake of radiocopper in primary biliary cirrhosis, together with the absence of any other significant tissue localization ofradioactivity, suggest strongly that both the liver uptake and hepatic excretory mechanisms for copper are adequate in this disease. However, in the presence of a raised pool of 'free' copper, the copper flux from plasma to liver and liver to plasma is increased. The slower but persistent rise in the liver radioactivity in Wilson's disease, together with the significantly impaired rate of plasma clearance of radiocopper, suggest both defective hepatic uptake and excretory mechanisms. The appearance of 64Cu-caeruloplasmin in the plasma after two to three hours was indeed deficient in Wilson's disease but we were unable to assess its quantitative importance in determining the continued accumulation of radiolabel in the Wilsonian liver. As we were unable to sample bile, liver, or other tissues apart from plasma at different times after the intravenous injection of "4CU, a complete kinetic analysis of copper transport in normal subjects and in patients with Wilsonian and non-Wilsonian cirrhosis was not possible. Despite these shortcomings, we have confirmed that there is a significant abnormality in the transport of copper by the liver in patients with Wilson's disease.
It is unlikely that the impaired uptake of copper in Wilson's disease is due to liver damage per se, insofar as the plasma clearance and hepatic uptake of radioactivity is unimpaired in patients with other forms of liver disease. The observation that there is some improvement in the rate of hepatic copper uptake after 'decoppering' patients with Wilson's disease by prolonged penicillamine therapy has led to the proposal that the impaired liver copper uptake is primarily an expression of the high liver copper concentration (Osborn and Walshe, 1967 It appears that the physiological mechanism for 143 hepatic copper uptake is by way of the lysosomes: Goldfischer and Sternlieb (1968) have observed this phenomenon in neonatal liver and it has been noted in rats and mice where experimentally induced hepatic copper deposits generally do not produce necrosis (Goldfischer, 1967; Barka, Scheuer, Schaffner, and Popper, 1964; Lindquist, 1967; Scheuer, Thorpe, and Marriott, 1967; Verity, Gambell, Reith, and Brown, 1967) . It is possible that delayed uptake of copper by the lysosomes in Wilson's disease may account for the present observations and for the toxic effects of the metal.
On the basis of the impaired hepatic uptake of radiocopper by patients with Wilson's disease, Walshe and his coworkers have suggested a diagnostic test for Wilson's disease in which the radioactivity over the liver is compared with that over a 'neutral' area, the thigh, at a given time after the intravenous injection of 64Cu (Osborn and Walshe, 1964) . Its prime usefulness was conceived to be in differentiating presymptomatic homozygotes from heterozygotes. More recently, Levi and Williams (1968) failed to confirm that the test was of any value in distinguishing between these two groups of patients. It should be pointed out that the present data, whilst confirming the abnormal hepatic uptake of copper in patients with Wilson's disease, are not directly comparable to these liver/thigh ratio studies. Whereas we have measured the sequential changes in radioactivity over each liver and drawn quantitative inferences from ancillary data in the same patient, the measurement of the liver/thigh ratio involves a between-patient comparison. Clearly, the surface counting characteristics could vary significantly between patients-depending upon the size, shape, and position of the liver. It is probable that these sources of measuring error account in large part for the differing results in the two studies discussed. Studies using the whole body counter to determine the body retention of copper appear to be more satisfactory in distinguishing between heterozygous carriers and homozygous normal individuals (Hamamoto et al, 1968; O'Reilly et al, 1969) .
The present study has indicated a defect in copper transport in the Wilsonian liver not attributable to the cirrhotic process or to the high liver copper concentration. The precise nature of this defect remains to be elucidated. Fortunately, a new experimental model system may be provided by the foetal or neonatal liver as present evidence suggests that the foetus and the patient with Wilson's disease may have features in common with respect to copper transport (Mearrick and Mistilis, 1969) , and may permit a critical evaluation of the hypothesis that the primary defect in Wilson's disease is delayed copper uptake by the lysosomes.
